Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ULTRA-HPV Using Circulating Tumor DNA to Risk Adapt Post-operative Therapy for HPV Associated Oropharyngeal Cancer

NCT06445114 is registered in ClinicalTrials.gov with Zachary Zumsteg as lead sponsor.

NCT NCT06445114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06445114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ULTRA-HPV Using Circulating Tumor DNA to Risk Adapt Post-operative Therapy for HPV Associated Oropharyngeal Cancer
Lead sponsor
Zachary Zumsteg
Phase
Phase 2
Overall status
Recruiting
Start date
May 12, 2025
Completion date
June 30, 2032
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, oropharyngeal cancer